New Proinsulin Study Findings Have Been Reported from T. Logan et al (Evaluating the Managed Care Implications of Longer-Acting Basal Insulin Analog…
New Proinsulin Study Findings Have Been Reported from
By a
The news correspondents obtained a quote from the research, "However, there are several barriers to its use. The introduction of the new, ultra-long-acting basal insulins degludec and glargine U-300, and the single-injection combinations of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide, offer options that may overcome several of those barriers, including the high risk of hypoglycemia, glycemic variability, and relatively short duration of action. This article spotlights the outcomes of the phase 3 clinical trials for these newer formulations, as well as more recent meta-analyses and real-world studies."
According to the news reporters, the research concluded: "It also highlights the implications for managed care plans as they move to add these insulins to their formularies."
For more information on this research see: Evaluating the Managed Care Implications of Longer-Acting Basal Insulin Analog Therapies.
Our news journalists report that additional information may be obtained by contacting
Keywords for this news article include:
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
Trademark Application for “BLUE SAVER” Filed by Blue Cross and Blue Shield Association
Onebeacon Insurance Group’s Trademark Application for “ONEBEACON MANAGEMENT LIABILITY” Filed
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News